Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mild Cognitive Impairment Due to Alzheimer's Disease: early-phase trial registry
1 of 2 indexed Mild Cognitive Impairment Due to Alzheimer's Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Mild Cognitive Impairment Due to Alzheimer's Disease: 2 US clinical trials tracked, 1 recruiting.
Mild Cognitive Impairment Due to Alzheimer's Disease is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 1 of these trials.
Enrollment posture brief
Registry condition mild-cognitive-impairment-due-to-alzheimers-disease
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Mild Cognitive Impairment Due to Alzheimer's Disease lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mild Cognitive Impairment Due to Alzheimer's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mild Cognitive Impairment Due to Alzheimer's Disease is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Brigham and Women's Hospital
NCT06489548
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Biogen
NCT05399888
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Mild Cognitive Impairment Due to Alzheimer's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mild Cognitive Impairment Due to Alzheimer's Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mild Cognitive Impairment Due to Alzheimer's Disease page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Mild Cognitive Impairment Due to Alzheimer's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Mild Cognitive Impairment Due to Alzheimer's Disease trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mild Cognitive Impairment Due to Alzheimer's Disease condition card totals 2 registered trials; most-linked intervention BIIB080-matching placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.